Density-dependent endothelial cell production of an inhibitor of smooth muscle cell growth.
Embryonic data and ultrastructural analyses suggest that the primitive endothelium signals undifferentiated mesenchymal cells to migrate to the forming blood vessel and subsequently regulates mural cell growth and behavior. Upon maturation of the blood vessel, chemotactic and mitogenic signals are apparently diminished and differentiated smooth muscle cells normally remain quiescent. This homeostasis is seemingly upset in conditions which lead to pathologies characterized by smooth muscle cell hyperplasia such as atherosclerosis. By culturing endothelial cells at different densities, we attempted to re-create the various stages of vascular development. Whereas media conditioned by sparse endothelial cells stimulate smooth muscle cells, media conditioned by dense endothelial cell cultures are inhibitory. Culture of sparse smooth muscle cells in media conditioned for 3 days by postconfluent endothelial cell cultures leads to dose-dependent and reversible smooth muscle cell inhibition. Furthermore, in the presence of the endothelial cell-derived inhibitor, smooth muscle cells are rendered refractory to mitogens such as fibroblast growth factor and platelet-derived growth factor. The inhibitory activity is not attributable to the well-characterized inhibitors of smooth muscle cell growth, transforming growth factor type-beta, prostaglandin I2, or heparan sulfate proteoglycan. Partial characterization of the inhibitory conditioned media suggests that the active molecule is smaller than 1,000 da, and stable to boiling as well as proteinase K and heparinase digestion. These findings support the concept that there is intercellular communication between endothelial cells and smooth muscle cells and provide evidence for a novel endothelial cell-derived smooth muscle cell growth inhibitor.
Dodge
A B
AB
Laboratory for Surgical Research, Children's Hospital, Boston, Massachusetts 02115.
Lu
X
X
D'Amore
P A
PA
D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002417:Cattle; D002452:Cell Count; D002455:Cell Division; D002478:Cells, Cultured; D017077:Culture Media, Conditioned; D004730:Endothelium, Vascular / Q000166:cytology / Q000378:metabolism*; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D006131:Growth Inhibitors / Q000096:biosynthesis* / Q000302:isolation & purification / Q000494:pharmacology; D006493:Heparin / Q000494:pharmacology; D019763:Heparin Lyase; D009131:Muscle, Smooth, Vascular / Q000166:cytology*; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011133:Polysaccharide-Lyases / Q000494:pharmacology; D011453:Prostaglandins / Q000302:isolation & purification; D016212:Transforming Growth Factor beta / Q000276:immunology / Q000494:pharmacology
D000906:Antibodies; D017077:Culture Media, Conditioned; D006131:Growth Inhibitors; D010982:Platelet-Derived Growth Factor; D011453:Prostaglandins; D016212:Transforming Growth Factor beta; D016222:Fibroblast Growth Factor 2; D006493:Heparin; D011133:Polysaccharide-Lyases; D019763:Heparin Lyase